CAS: 70951-85-8; 4-Bromo-1-(Tert-Butyl)-1H-Pyrazole

相似化合物

95162-14-4 313735-62-5 2088840-42-8

上下游产品

CAS号15754-60-6 1-叔丁基吡唑 | CAS号1256359-15-5 1-(叔丁基)-4-(4,4,...

1-叔丁基吡唑置于n-溴代丁二酰亚胺(Nbs)体系中,用 二氯甲烷 作为反应溶剂,化学反应 0.5H,以34 G的收率获得产物4-溴-1-叔丁基-1H-吡唑
参考文献: Pyrazolyl-Substituted Heteroaryls And Their Use As Medicaments[fr] Hétéroaryles à Substitution Pyrazolyle Et Leur Utilisation En Tant Que Médicaments
标题: Pyrazolyl-Substituted Heteroaryls And Their Use As Medicaments[fr] Hétéroaryles à Substitution Pyrazolyle Et Leur Utilisation En Tant Que Médicaments
摘要:该发明涉及新的取代杂环芳基化合物,其化学式为1或1',其中a为n或ch,R2选自-C1-3-烷基,-C1-3-卤代烷基,F,Br,Cl,Y选自-O-或-Ch2-,R3如权利要求1所定义,以及其药用盐,以及这些化合物用于治疗哮喘,慢性阻塞性肺病,过敏性鼻炎,过敏性皮炎,红斑狼疮,红斑狼疮性肾炎和类风湿性关节炎等疾病.

专利信息

专利号:US-7897762-B2
优先权日:2006-09-14
标 题:Kinase inhibitors useful for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:DECIPHERA PHARMACEUTICALS LLC
摘要:The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

专利号:US-8188113-B2
优先权日:2006-09-14
标 题 :Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C; DECIPHERA PHARMACEUTICALS INC
摘要:The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

专利号:US-2009137566-A1
优先权日:2005-05-26
标 题 :Substituted Piperdines as Renin Inhibitors
发明人：EHARA TAKERU; HITOMI YUKO; KONISHI KAZUHIDE; MASUYA KELICHI
权利人:EHARA TAKERU; HITOMI YUKO; KONISHI KAZUHIDE; MASUYA KELICHI
摘要:The invention relates to substituted 3,4- or higher substituted piperididine compounds, the use thereof for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; pharmaceutical formulations or products comprising said compounds, and/or a method of treatment comprising administering said compounds, a method for the manufacture of said compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis. The compounds preferably have the formula I, n n n n n n n n n n wherein the moieties R1, R2, R11 and W are as defined in the specification.